ARTICLE | Finance
Novo ventures into Asia with Hummingbird’s series C round
The investment signals more to come for Novo’s new Singapore office
May 18, 2021 9:44 AM UTC
Novo Ventures is making its first foray into Asia through a $125 million series C round for Singapore-based Hummingbird, which has two programs nearing the clinic that demonstrate the biotech’s ability to hit difficult-to-drug targets.
The cash should give Hummingbird Bioscience Pte. Ltd. enough capital to push its two lead programs to clinical proof-of-concept and further build out its Rational Antibody Discovery platform...